Home > Back to Publisher > Report Information

Antivirals: Global Anti-Infectives Markets Vol I

PJB Publications USA Inc.
October 1, 2003
232 Pages - SKU: VB935366

Abstract Table of Contents Search inside this report Related Reports

Countries covered: Global

Antivirals: Global Anti-Infectives Markets Vol I

Antiviral drugs are the main, if only, method of treatment of major viral disease conditions. This Theta Report is the first in a three-volume series of market research reports on global anti-infective drug markets.

In order to recognize the opportunities presented by the antiviral pharmaceuticals market, companies need to be aware of treatment advances, as well as probable future offerings and their projected impact on future drug sales. This report presents global market analysis by geographic region and by major drug products, as well as competitive positions of major players and competitive dynamics affecting market change.

Major viral disease conditions for which antivirals are used as in this report are:

Hepatitis B
Hepatitis C
Human immunodeficiency virus (HIV)
Herpes virus
Influenza
Respiratory syncytial virus (RSV)
Human papillomavirus (HPV)

Classes of antiviral drugs discussed include:

Interferons
Nucleoside reverse transcriptase inhibitors (NRTIs)
Non-nucleoside reverse transcriptase inhibitors (nNRTIs)
Protease inhibitors
Other drugs: anti-influenza agents, neuraminidase inhibitors, immunoglobulins, immunomodulators

An essential strategic resource, Theta’s Antivirals: Global Anti-Infectives Markets Vol. I answers the following questions:

What conditions currently require treatment with antivirals?
What are the healthcare costs of these conditions?
Why are these conditions such a problem?
What antiviral products are currently available to treat these conditions?
What antiviral products are currently in development for these conditions?
What are the current market sizes and forecasted market projections for antiviral drugs for each condition, based on drug class/product and geographic region?
Who are the major competitors and what are their current market shares?

Please Note: Theta requires that, for PDF orders, clients sign a confidentiality agreement prior to fulfillment of PDF email delivery.

1 Executive Summary

1.1 Scope and Objectives of the Report
1.2 Methodology

2 Introduction and Overview

2.1 Definition of Antiviral Drugs
2.2 Classes of Antiviral Drugs
2.2.1 Interferons
2.2.2 Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
2.2.3 Non-Nucleoside Reverse Transcriptase Inhibitors (nNRTIs)
2.2.4 Protease Inhibitors
2.3 Disease Conditions for Use
2.4 Prevalence and Demographics

3 Issues and Trends in Antivirals

3.1 Health and Economic Consequences
3.2 Legislative and Industry Actions Impacting Antivirals
3.3 Medical and Development Issues
3.3.1 Antiviral Drug Resistance
3.3.2 Patent Expirations
3.4 Severe Acute Respiratory Syndrome (SARS)
3.4.1 A New Viral Condition
3.4.2 Drugs and Diagnostics in Development

4 Hepatitis B

4.1 Overview of Condition
4.1.1 Risk Factors
4.1.2 Incidence/Mortality
4.1.3 Diagnostics
4.2 Treatments
4.2.1 INTRON A
4.2.2 Epivir-HBV/Zeffix
4.2.3 Hepsera
4.3 Research and Development
4.4 Global Market Analysis
4.4.1 Total World Market Size and Growth
4.4.2 U.S. Market Size and Growth
4.4.3 Western European Market Size and Growth
4.4.4 Japanese Market Size and Growth
4.4.5 Rest of World Market Size and Growth
4.5 Competitor Analysis

5 Hepatitis C

5.1 Overview of Condition
5.1.1 Risk Factors
5.1.2 Incidence/Mortality
5.1.3 Diagnostics
5.2 Treatments
5.2.1 INTRON A
5.2.2 Roferon A
5.2.3 Infergen
5.2.4 PEG-Intron
5.2.5 Pegasys
5.2.6 Rebetron
5.2.7 Rebetol
5.2.8 Copegus
5.3 Research and Development
5.4 Global Market Analysis
5.4.1 Total World Market Size and Growth
5.4.2 U.S. Market Size and Growth
5.4.3 Western European Market Size and Growth
5.4.4 Japanese Market Size and Growth
5.4.5 Rest of World Market Size and Growth
5.5 Competitor Analysis

6 Human Immunodeficiency Virus (HIV)

6.1 Overview of Condition
6.1.1 Risk Factors
6.1.2 Incidence/Mortality
6.1.3 Diagnostics
6.2 Treatments
6.2.1 Fortovase/Invirase
6.2.2 Norvir
6.2.3 Crixivan
6.2.4 Viracept
6.2.5 Agenerase
6.2.6 Kaletra
6.2.7 Reyataz
6.2.8 Retrovir/AZT
6.2.9 Epivir
6.2.10 Combivir
6.2.11 Hivid
6.2.12 Videx
6.2.13 Trizivir
6.2.14 Zerit
6.2.15 Ziagen
6.2.16 Viread
6.2.17 Viramune
6.2.18 Rescriptor
6.2.19 Sustiva
6.3 Research and Development
6.4 Global Market Analysis
6.4.1 Total World Market Size and Growth
6.4.2 U.S. Market Size and Growth
6.4.3 Western European Market Size and Growth
6.4.4 Japanese Market Size and Growth
6.4.5 Rest of World Market Size and Growth
6.5 Competitor Analysis

7 Herpes Simplex Virus

7.1 Overview of Conditions
7.1.1 Risk Factors
7.1.2 Incidence/Mortality
7.1.3 Diagnostics
7.2 Treatments
7.2.1 Valtrex
7.2.2 Famvir
7.2.3 Zovirax
7.2.4 Natural Products
7.3 Research and Development
7.4 Global Market Analysis
7.4.1 Total World Market Size and Growth
7.4.2 U.S. Market Size and Growth
7.4.3 Western European Market Size and Growth
7.4.4 Japanese Market Size and Growth
7.4.5 Rest of World Market Size and Growth
7.5 Competitor Analysis

8 Other: Influenza, RSV, HPV

8.1 Overview of Conditions
8.1.1 Risk Factors
8.1.2 Incidence/Mortality
8.1.3 Diagnostics
8.2 Treatments
8.2.1 Tamiflu
8.2.2 Relenza
8.2.3 Amantadine and Rimantadine
8.2.4 Ribavirin
8.2.5 Aldara
8.2.6 Condylox
8.3 Research and Development
8.4 Global Market Analysis
8.4.1 Total World Market Size and Growth
8.4.2 U.S. Market Size and Growth
8.4.3 Western European Market Size and Growth
8.4.4 Japanese Market Size and Growth
8.4.5 Rest of World Market Size and Growth
8.5 Competitor Analysis

9 Overall Market Summary

9.1 Total World Market Size: 2002, 2008
9.2 World Markets by Viral Condition: 2002, 2008
9.3 World Markets by Geographic Region: 2002, 2008

10 Company Briefs

10.1 Abbott Laboratories
10.2 Boehringer Ingelheim GmbH
10.3 Bristol-Myers Squibb
10.4 GlaxoSmithKline plc
10.5 MedImmune Inc.
10.6 Merck & Co., Inc.
10.7 3M
10.8 Pfizer Inc.
10.9 F. Hoffmann-La Roche & Co.
10.10 Schering-Plough Corp.

More Global Infectious Diseases Reports

2012 World Infectious Disease Testing Market Overview: Facilities, Test Volumes, and Sales Forecasts by Country by Venture Planning Group
This report provides a worldwide overview of the infectious disease testing market environment, structure, size and growth. Includes estimates of the number of laboratories ...

2012 Global Infectious Disease Testing Market Outlook: Growth Opportunities and Strategies by Venture Planning Group
The infectious disease testing market is one of the most rapidly growing segments of the in vitro diagnostics industry, and the greatest challenge facing suppliers ...

Global Infectious Disease Treatment Market 2011-2014 by Infiniti Research Limited
TechNavio’s analysts forecast the Global Infectious Disease Treatment market to grow at a CAGR of 8.1 percent over the period 2011–2014. One of the key ...

World Market for Anti-Infectives: Antifungals, Antibacterials and Antivirals (Treatments for HIV, HBV, HCV, Urinary Tract, Respiratory, Candidiasis and Other Infections) by Kalorama Information
This Kalorama Information report – The World Market for Anti-Infectives - focuses on three key segments of treatment: Antifungals (Allylamines, Azoles, ...

Future Infectious Disease Testing Market: Growth Opportunities, Business Strategies, Market Entry Barriers and Risks by Venture Planning Group
The report identifies the major opportunities for infectious disease testing instrumentation, reagent kits/test panels, consumables, as well as IT and auxiliary products; proposes design criteria ...

See all reports like this >>

Antivirals: Global Anti-Infectives Markets Vol I

Share this report

Other tasks

Research Assistance

Related Markets

Infectious Diseases Reports

Free Alert Me service